The combination of atezolizumab (anti-PD-L1) and bevacizumab (anti-VEGF (vascular endothelial growth factor)) was the first regimen to show an improvement in overall survival (OS) versus sorafenib in the first-line systemic treatment of HCC [15], establishing a new standard of care. This evidence concerns the gene VEGFA and hepatocellular carcinoma.